Acorda Therapeutics Inc (ACOR) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have been assigned a consensus rating of “Hold” from the eighteen ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $21.69.

Several equities research analysts recently issued reports on the company. ValuEngine cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. Goldman Sachs Group upgraded Acorda Therapeutics from a “sell” rating to a “neutral” rating in a research note on Wednesday, February 7th. Oppenheimer boosted their price target on Acorda Therapeutics from $18.00 to $21.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target (down from $34.00) on shares of Acorda Therapeutics in a research note on Wednesday, January 17th. Finally, Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th.

In other news, insider Burkhard Blank sold 11,050 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the transaction, the insider now directly owns 33,150 shares in the company, valued at approximately $680,569.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Lawrence sold 31,000 shares of the stock in a transaction on Friday, January 19th. The shares were sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the transaction, the insider now owns 5,275 shares of the company’s stock, valued at $145,484.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of ACOR. American International Group Inc. boosted its position in shares of Acorda Therapeutics by 5.6% during the 3rd quarter. American International Group Inc. now owns 34,712 shares of the biopharmaceutical company’s stock worth $821,000 after purchasing an additional 1,839 shares in the last quarter. Voya Investment Management LLC lifted its position in Acorda Therapeutics by 10.1% in the 2nd quarter. Voya Investment Management LLC now owns 20,633 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 1,897 shares in the last quarter. California Public Employees Retirement System lifted its position in Acorda Therapeutics by 3.2% in the 2nd quarter. California Public Employees Retirement System now owns 64,400 shares of the biopharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 2,000 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in Acorda Therapeutics by 10.0% in the 4th quarter. UBS Asset Management Americas Inc. now owns 23,177 shares of the biopharmaceutical company’s stock valued at $497,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Alps Advisors Inc. lifted its position in Acorda Therapeutics by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 45,944 shares of the biopharmaceutical company’s stock valued at $1,087,000 after acquiring an additional 3,829 shares in the last quarter.

Shares of Acorda Therapeutics (NASDAQ:ACOR) traded up $0.20 during mid-day trading on Wednesday, hitting $24.95. The company had a trading volume of 393,500 shares, compared to its average volume of 790,417. The company has a current ratio of 2.77, a quick ratio of 2.40 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $1,156.99, a PE ratio of -20.62 and a beta of 1.63. Acorda Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $33.00.

TRADEMARK VIOLATION NOTICE: This report was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/acorda-therapeutics-inc-acor-receives-consensus-recommendation-of-hold-from-analysts.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply